NICO - a national prospective non-interventional Study (NIS) with Nivolumab as Monotherapy or in combination with Ipilimumab in Patients with advanced (inoperable or metastatic) Melanoma to collect real-world data

被引：0
|
作者：
Gutzmer, R. [1 ]
Eigentler, T. [2 ]
Mohr, P. [3 ]
Becker, S. [4 ]
Haferkamp, S. [5 ]
Meiss, F. [6 ]
Pfoehler, C. [4 ]
Satzger, I. [7 ]
Schneider, S. W. [8 ]
Terheyden, P. [9 ]
Ulrich, J. [10 ]
Utikal, J. [11 ]
Weichenthal, M. [12 ]
Weishaupt, C. [13 ]
Zimmer, L. [14 ]
Schadendorf, D. [14 ]
机构：
[1] Hannover Med Sch, Klin Dermatol Allergol & Venerol, Haut Tumor Zentrum, Hannover, Germany
[2] Eberhard Karls Univ Tubingen, Tubingen, Germany
[3] Elbe Kliniken Buxtehude, Buxtehude, Germany
[4] Univ Klinikum Saarlandes, Homburg, Germany
[5] Univ Klinikum Regensburg, Regensburg, Germany
[6] Univ Klinikum Freiburg, Freiburg, Germany
[7] Hannover Med Sch, Hannover, Germany
[8] Univ Klinikum Hamburg Eppendorf UKE, Hamburg, Germany
[9] Univ Klinikum Schleswig Holstein, Lubeck, Germany
[10] Harzklinikum Dorothea Christiane Erxleben GmbH, Quedlinburg, Germany
[11] Univ Klinikum Mannheim, Mannheim, Germany
[12] Univ Klinikum Schleswig Holstein, Kiel, Germany
[13] Univ Klinikum Munster, Munster, Germany
[14] Univ Klinikum Essen, Essen, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2018年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P131
引用
收藏
页码：79 / 79
页数：1
相关论文
共 50 条
  • [31] "Real-world" data on the use of ruxolitinib in myelofibrosis: 2018 interim analysis of the prospective, non-interventional study JAKoMo
    Koschmieder, S.
    Jacobasch, L.
    Schulte, C.
    Geer, T.
    Brudler, O.
    Wehmeyer, J.
    Klausmann, M.
    Groeschl, B.
    Grosser, S.
    Pahl, H. L.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 98 - 99
  • [32] Comparison of effectiveness and safety of nivolumab monotherapy or in combination therapy with ipilimumab in therapy-naive and pretreated patients with advanced melanoma within the German noninterventional study NICO
    Gutzmer, R.
    Eigentler, T.
    Mohr, P.
    Weichenthal, M.
    Duecker, P.
    Gebhardt, C.
    Goeppner, D.
    Grimmelmann, I.
    Haferkamp, S.
    Kaehler, K. C.
    Meier, F.
    Pfoehler, C.
    Sickmann, T.
    Sindrilaru, A.
    Terheyden, P.
    Ugurel, S.
    Ulrich, J.
    Utikal, J.
    Weishaupt, C.
    Schadendorf, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S894 - S895
  • [33] Hanna - Real-World Data from a Non-Interventional Study Assessing Routine Use of Nivolumab in Patients with Recurrent or Metastatic Cancer of the Head and Neck (R/M SCCHN) in Germany
    Welslau, Manfred
    von der Heyde, Eyck
    Gauler, Thomas
    Hahn, Dennis
    Bockmuehl, Ulrike
    Wittekindt, Claus
    Mueller-Huesmann, Harald
    Busch, Chia-Jung
    Mauz, Paul-Stefan
    Waldenberger, Daniela
    Dietz, Andreas
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 96 - 96
  • [34] HEALTH CARE COST COMPARISON ANALYSIS OF NIVOLUMAB plus IPILIMUMAB REGIMEN AND NIVOLUMAB MONOTHERAPY VERSUS ESTABLISHED ADVANCED MELANOMA THERAPIES UTILIZING CLINICAL TRIAL AND REAL-WORLD DATA
    Potluri, R.
    Okoro, T.
    Bhandari, H.
    Sabater, J.
    Ranjan, S.
    Kotapati, S.
    VALUE IN HEALTH, 2016, 19 (03) : A144 - A144
  • [35] Efficacy and Safety of Brivaracetam in Persons With Epilepsy in a Real-World Setting: A Prospective, Non-Interventional Study
    Siddiqui, Fowzia
    Soomro, Bashir A.
    Badshah, Mazhar
    Rehman, Ehsan U.
    Numan, Ahsan
    Ikram, Amer
    Khan, Muhammad Wazir Ali
    Ali, Sajjad
    Hashim, Husnain
    Salam, Jawwad-us
    Akram, Asad
    Hashmat, Muhammad Irfan
    Iqbal, Shahid
    Javed, Muhammad Zeeshan
    Iqbal, S. Zafar
    Maqsood, Atif
    Khan, Assadullah
    Maheshwary, Neeta
    Khan, Muhammad Athar
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (12)
  • [36] Prospective, Non-interventional Study on the Real-World Use of Certoparin in Daily Practice-The PROMEMBER Study
    Spannagl, Michael
    Melzer, Nima
    Bramlage, Peter
    Englert, Cornelia
    Eisele, Ralf
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2013, 19 (01) : 86 - 91
  • [37] Encorafenib plus Binimetinib in Patients with locally advanced, inoperable, or metastatic BRAFV600 mutated Melanoma: First Data from the multicenter, multinational, prospective, non-interventional Longitudinal Study BERINGMELANOM
    Richtig, E.
    Debus, D.
    Stadler, R.
    Hoeller, C.
    Utikal, J. S.
    Dummer, R.
    Haferkamp, S.
    von Moos, R.
    Michielin, O.
    Schadendorf, D.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 81 - 82
  • [38] Encorafenib and Binimetinib Combination in Patients with locally advanced, inoperable or metastatic BRAFV600 mutant Melanoma: A multi-centre, multinational, prospective, non-interventional Longitudinal Study in Germany and Austria - BERINGMELANOM
    Schadendorf, D.
    Haferkamp, S.
    Richtig, E.
    Hoeller, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 75 - 75
  • [39] Persistence with Denosumab in Male Osteoporosis Patients: A Real-World, Non-Interventional Multicenter Study
    Jeong, Chaiho
    Lee, Jeongmin
    Kim, Jinyoung
    Ha, Jeonghoon
    Jo, Kwanhoon
    Lim, Yejee
    Kim, Mee Kyoung
    Kwon, Hyuk-Sang
    Sohn, Tae-Seo
    Song, Ki-Ho
    Kang, Moo Il
    Baek, Ki-Hyun
    ENDOCRINOLOGY AND METABOLISM, 2023, 38 (02) : 260 - 268
  • [40] Real-world comparison of outcomes in the first line treatment of metastatic melanoma according to BRAF mutation status: Nivolumab and ipilimumab therapy vs. nivolumab monotherapy.
    Klein-Brill, Avital
    Amar-Farkash, Shlomit
    Fisch, Michael Jordan
    Aran, Dvir
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345